Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: GlobalData
$125.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Antisense Therapeutics Ltd announces positive results achieved from interim analysis of ATL1103 phase II trial


Sunday, 22 Dec 2013 10:04pm EST 

Antisense Therapeutics Ltd:Says positive results have been achieved from the interim analysis of a subset of available data from its phase II clinical trial of ATL1103 in patients with the growth disorder, acromegaly.Says the interim analysis was undertaken on the eight patients who have completed the full three months of dosing at both dosing levels employed in the study.Says four patients received 200 mg of ATL1103 once per week and four received the higher dose of 200 mg twice per week (400 mg).Says the interim analysis assessed the change (percentage reduction) from each patient’s baseline (start of the study) serum Insulin-like Growth Factor-I (sIGF-I) levels to their levels after the completion of dosing with ATL1103.Says reducing sIGF-I levels is the primary marker of ATL1103 activity in this trial as acromegaly patients have elevated sIGF-I levels compared to the normal population.Says furthermore, reduction of sIGF-I to within the normal range in a significant proportion of patients is the goal in Phase III registration trials for acromegaly treatments. 

Company Quote

0.14
0.01 +7.69%
29 Jul 2014